prof. MUDr. Jiří Mayer, CSc.
Department head, Department of Internal Medicine, Hematology and Oncology
Correspondence Address:
Jihlavská 340/20, 625 00 Brno
Phone: | +420 532 23 3643, 3603 |
---|---|
E‑mail: |
social and academic networks: |
---|
Total number of publications: 1617
2022
-
Successful early use of anti-SARS-CoV-2 monoclonal neutralizing antibodies in SARS-CoV-2 infected hematological patients - A Czech multicenter experience
Hematological Oncology, year: 2022, volume: 40, edition: 2, DOI
-
Školení klinického hodnocení pro IHOK
Year: 2022, type: Workshop
-
Tesidolumab (LFG316) for treatment of C5-variant patients with paroxysmal nocturnal hemoglobinuria
Haematologica, year: 2022, volume: 107, edition: 6, DOI
-
The Prognostic Impact of HMGCLL1 Gene Variant on Treatment Outcomes in Chronic Myeloid Leukemia (CML) Patients: Adverse Impact on the Response, Failure, and Progression with Imatinib Which Can be Abrogated By the Use of 2nd Generation Tyrosine Kinase Inhibitor (TKI) Upfront Therapy
Year: 2022, type: Conference abstract
-
Versatile coculture systém to study chronic lymhocytic leukemia proliferation.
Year: 2022, type: Conference abstract
-
Very rare near-haploid acute lymphoblastic leukemia resistant to immunotherapy and CAR-T therapy in 19-year-old male patient
CLINICAL CASE REPORTS, year: 2022, volume: 10, edition: 3, DOI
2021
-
Acute myeloid leukemia regression induced by palbociclib and ponatinib in patient –derived xenograft model.
Year: 2021, type: Conference abstract
-
Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing BCR-ABL1(T315I)-compound mutations
AMERICAN JOURNAL OF CANCER RESEARCH, year: 2021, volume: 11, edition: 9
-
Cévní nežádoucí účinky u pacientů s chronickou myeloidní leukemií při terapii inhibitory tyrozinkináz v každodenní klinické praxi – analýza z databáze INFINITY
Year: 2021, type: Conference abstract
-
CLLEAR – Czech national registry of CLL patients: complete data analysis 2021.
Year: 2021, type: Conference abstract